CytoSorbents flags new CytoSorb clinical data presentations at EACTS, ESICM conferences
Bitget2026/09/30 11:04- CytoSorbents flagged new clinical data on its CytoSorb blood purification device for presentation at EACTS and ESICM in October 2026.
- Results have not yet been presented; the company outlined scheduled talks spanning cardiac surgery bleeding risk, post-surgery shock, ECMO-related inflammation, sepsis, ARDS.
- Presentations are set to highlight real-world registry experience, with outcomes framed around improved management of hyperinflammation and organ dysfunction in critical illness.
- The updates center on the COSMOS Registry, a key evidence-building program that could support broader clinical adoption across cardiac surgery and ICU use-cases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ido Ben-Natan: Frequent on-chain security incidents, AI agents will increase risks
BTC rebounds and breaks through 83,000 USDT, with a 24-hour decrease of 1%
Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly
The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Crypto prices
More
